- Home
- HOOK
HOOK
HOOKIPA Pharma Inc.
as 05-30-2025 4:00pm EST
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 9.3M | IPO Year: | 2019 |
| Target Price: | $10.67 | AVG Volume (30 days): | 205.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $9.09 | Next Earning Date: | 05-15-2025 |
| Revenue: | $9,351,000 | Revenue Growth: | -82.54% |
| Revenue Growth (this year): | -55.32% | Revenue Growth (next year): | -94.81% |
Latest HOOKIPA Pharma Inc. News
HOOK Breaking Stock News: Dive into HOOK Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Gilead (GILD) to Acquire HOOK for $10 million
MT Newswires
9 days ago
HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise
GlobeNewswire
3 months ago
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
TipRanks
4 months ago
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial
GlobeNewswire
4 months ago
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
MT Newswires
5 months ago
HC Wainwright Downgrades HOOKIPA Pharma to Neutral From Buy
GlobeNewswire
5 months ago
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
GlobeNewswire
5 months ago
HOOKIPA Pharma Inc - FORM 8 (OPD)
Compare HOOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOOK HOOKIPA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.